« Celgene Triumphs in Legal Battle over Revlimid Patent: Curation of Patents, Litigations, and Impact on Drug Pricing

Pancreatic cancer survival is determined by ratio of two enzymes »

LIVE Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 28, 2019

March 28, 2019 by 2012pharmaceutical

LIVE Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 28, 2019

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media

@pharma_BI

@AVIVA1950

#StateofPossible19

Day 2 Agenda – March 28, 2019

Possible Talk – The New Role of Police: Creating Non-Arrest Pathways to Treatment and Recovery	Conference Wide	3/28/2019 8:45:00 AM	3/28/2019 9:00:00 AM
Future of Human Biology: How we are Already Evolving Ourselves	Conference Wide	3/28/2019 9:00:00 AM	3/28/2019 9:45:00 AM
Possible Talk – The Evolution of the Investment Landscape to Support Future Innovations in Biotech	Conference Wide	3/28/2019 9:45:00 AM	3/28/2019 10:00:00 AM
CFIUS: Proposed Rules Impacting Global Investments for Biotech	Breakout – Business Track	3/28/2019 10:15:00 AM	3/28/2019 11:00:00 AM
Exploring the Possibilities of Microbiome Beyond GI Diseases	Breakout – Science Track	3/28/2019 10:15:00 AM	3/28/2019 11:00:00 AM
Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies	Breakout – Science Track	3/28/2019 11:30:00 AM	3/28/2019 12:15:00 PM
Financing Outlook for 2019-2020: Will the Bubble Burst?	Breakout – Business Track	3/28/2019 11:30:00 AM	3/28/2019 12:15:00 PM
Lunch & Henri Termeer Innovative Leadership Award	Conference Wide	3/28/2019 12:15:00 PM	3/28/2019 1:15:00 PM
Enabling Digital Health in the Healthcare Value Chain	Conference Wide	3/28/2019 1:15:00 PM	3/28/2019 2:00:00 PM

Day 2 Agenda – March 28, 2019

8:15am – 8:45am: Breakfast

8:45am – 9:00am: Possible Talk

Possible Talk – The New Role of Police: Creating Non-Arrest Pathways to Treatment and Recovery

Treatment of excellence in opiods draws patients fro all the MA state to Boston Programs and from Outside of MA
94% walking on the door receive referrals to treatment centers in MA
Prediction of the future of persistence of the phonomenon
Funding partnerships for reducing time in treatment due to efficacy and patients engagement
500 police personnel are involved in Treatment available on Demand referral
Substance abuse programs that work using institutions as problem solvers
Urgent and important because people die every day

9:00am – 9:45am: Future of Human Biology: How we are Already Evolving Ourselves

Megan Thielking, STAT News

Ethics of Human germ line

George M. Church PhD, Professor of Genetics, Harvard Medical School

Multiplexing and gene editing for reverse aging
Doing to much by adding new forms somatic therapies feedback loop is long from young adults to aging
Small pox: Gene therapy can becaome non expensive

Juan Enriquez, Managing Director, Excel Venture Management, Prof. @Harvard in Genomics and Manage Start up in Genomics

conception – identical twins bred 20 years apart
fetus external to body and male can have children

Greg Verdine, President, CEO & CSO, Board Member, LifeMine

Embryos IVF,, fully sequence the embroy and
Democratice technologies at high school age –
Educators will play a role for informed decisions public education
AI harder to democratize
Ethics consideration in patient selection for certification

9:45am – 10:00am: Possible Talk –

Possible Talk – The Evolution of the Investment Landscape to Support Future Innovations in Biotech

communication what Biotech do, how position biotech start up and how raise fund
Thematic Investing: ALPHA CURRENTS: AI, Medical Technologies, communication technologies
Mother test – Communication of thoughts

10:15am – 11:00am: CFIUS: Proposed Rules Impacting Global Investment for Biotech [Business Track]

Review committee foreign investment, purchasing entire company –
new regulation 8% foreign investment is the largest allowed share as equity position and
not to negatively affect cyber security and national security
In BioTech (i.e. gene editing technologies developed already overseas and all other ecosystems
Green Card Holder investor are not excempt of CFIUS is different that US Citizen Investors which are exempts

Vikas Goyal, Principal, S. R. One, GlasxoSK Limited
Linda Ji, Partner, McDermott Will & Emory

Disclosure about the investment and investors
neurotech, genetics, genomics
Critical tech in Biotech: Foundational vs
US EXPERT CONTROLLED Technology
License needed for licensing US EXPERT CONTROLLED Technology
CFIUS does not handle licensing

Lisa Schaefer, Director of Financial Services and Tax Policy, Biotechnology Innovation Organization (BIO)

Expert controlled technology
AI in Drug discovery -is emerging foundational technology

Johhy Hu – VC in Boston – FUND owners are Swiss & Italian citizenship

10:15am – 11:00am: Exploring the Possibilities of Microbiome Beyond GI Diseases [Science Track]

David Donabedian, Co-founder, CEO & Director, Axial Biotherapeutics
Justin Chakma, Head of BD and Strategy, Vedanta
Chris Howerton, Biotechnology Equity Analyst, Jeffries

11:00am – 11:30am: Networking Break

11:30am – 12:15pm: Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies [Science Track]

Laura Indolfi, Founder & CEO, PanTher Therapeutics
Sven Karlsson, Co-Founder, CEO,& CBO, Platelet Biogenesis
Leslie Williams, Director, Founder, President and CEO, ImmusanT

11:30am – 12:15pm: Financing Outlook for 2019-2020: Will the Bubble Burst? [Business Track]

Bruce Booth, Partner, Atlas Ventures

Great time of capital rich, 2018 2Q – largest M&A in Biotech
staggering increase in funding
capital is flowing not from VCs, bur large hedge funds and foreign investment – China related 40% and Abu Dabi invest in Biotech
First IPO in 2012 was Biotech
Investor more selective and descerned : Preclinical Phase 1
2009-2010 – cool off market
2019 at constructive market for growing companies

Kathy Bersteinsson, Morgan Stanley

$30 Billion in 2018
8 IPO, back
2019 will be constructive, capital for biotech ecosysytem 50Billion needed, @25 Billion is secured without convertibles
back log of IPO for 2Q in 2019
investors wish 30% returns – adjust IPO valuation some are 1.5 times and fees on top
Investors willing to participate VC not participate in good markets
Good IPO no VCs
Oncology, Selling genes, CNS
Maturing the crop takes time

Christine Brennan, Partner, MRL Ventures Fund, Merck US

RNA landscape
oncology

Barbara Dalton, Pfizer Ventures

Neurosciences, Biogen failure, need for new drugs
Newrodegeneration
Venture group does invest in neuro because Pfizer left Neuro
investment in IMMUNITY
M&A pipeline to move the needle does not happens for small biotech
Pfizer and all BIG Pharma do not but even though Tax Reform favor Big Pharma

Steve Wilcox, Lawyer – largest Biotech

what is hot and not
Option to Purchase is lousy for sellers you cap the upper bound

12:15pm – 1:15pm: Lunch and MassBio Innovation Award Presentation

Lita Nelson, fear of genetics lead to development of 1980s legislation ownership and Patent exploitation by institutions, Universities started to collect royalties from Tech Transfer, Gov’t supported 120 Billion in basic research since the 70s.
200 Research Universities and Hospitals Tech Transfer Office research shows:
6300 licenses granted
early investment in innovations – in MA, 30 years ago no Pharma in MA today 18 of 20 big Pharma are in Cambridge and other locations in mA
People: accelerate biotech faced scarce talent not scarce capital
networking – dense clusters in Cambridge
Cambridge is the envy of the World in BioTech

1:15pm – 2:00pm: Enabling Digital Health in the Healthcare Value Chain

Moderator: Hussain Mooraj, Delloitte

Jeff Elton, CEO, Concerto Health AI
Cluster of centers of excellence
Moderna, VP IT

cross pollination =: CS + Biology form MIT
Top management understand technologies in Biotech
data collection
blueprint to design a digital platform – from the start to do it right vs retrofits at later stage

Luba Greenwood, Google – Verily – IP was the asset in 2019 it is the DATA not the IP – use of data to improve drug discovery

Starting up a Biotech company
Advice is available

ThermoFischer – R&D DIgital Science,
Pear Therapeutics, Brooke Paige, VP, Alliance ManagementBrooke Page

2:00pm – 2:30pm: Keynote Address

2:30pm – 3:00pm: Closing Networking Dessert Reception

@@@@@

8:15am – 8:45am: Breakfast

8:45am – 9:00am: Possible Talk

9:00am – 9:45am: Future of Human Biology: How we are Already Evolving Ourselves Humans began changing our environment early on through fire, agriculture and early medicines, and later with biopharmaceuticals and even CRISPR babies. Come hear futurists in human biology offer provocative thoughts on how we can wisely and ethically embrace next generation science to change our own DNA. – George M. Church Phd, Professor of Genetics, Harvard Medical School – Juan Enriquez, Managing Director, Excel Venture Management – Greg Verdine, President, CEO & CSO, Board Member, LifeMine

9:45am – 10:00am: Possible Talk

10:15am – 11:00am: CFIUS: Will New Regulatory Threats Reduce Global Investment in Biotech? [Business Track] CFIUS’ newly expanded scope and authority have the potential to severely disrupt investment in the U.S. biotech sector. A new federal law now includes biotechnology on a list of 27 “critical” industries where all foreign investment must be reviewed by the CFIUS office. With this new rule in place, questions abound about its impact on the biotech industry. Will raising money take longer? Will it deter foreign investors? Will it limit companies’ leverage during investment negotiations? Come hear legal, investor, and company experts discuss what companies and investors need to know about CFIUS’ impact on future investments in biotech companies. – Vikas Goyal, Principal, S. R. One, Limited – Linda Ji, Partner, McDermott Will & Emory – Lisa Schaefer, Director of Financial Services and Tax Policy, Biotechnology Innovation Organization (BIO)

10:15am – 11:00am: Exploring the Possibilities of Microbiome Beyond GI Diseases [Science Track] The specific balance of bacteria in your gut affects your digestive system, but new research also shows these bacteria affect your behavior, energy, heart, brain and other unexpected organ systems. Pioneers in microbiome expound on the possibilities. – David Donabedian, Co-founder, CEO & Director, Axial Biotherapeutics – Justin Chakma, Head of BD and Strategy, Vedanta – Chris Howerton, Biotechnology Equity Analyst, Jeffries

11:00am – 11:30am: Networking Break

11:30am – 12:15pm: Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies [Science Track] Massachusetts is the epicenter of startup creation for biotech, but it’s not always easy to go from research to commercialization. Come hear founders and industry leaders offer lessons learned on intelligently scaling your company amid rapid growth including when to partner, sell or IPO, or when to build or buy preclinical, manufacturing, and clinical development capabilities. – Laura Indolfi, Founder & CEO, PanTher Therapeutics – Sven Karlsson, Co-Founder, CEO,& CBO, Platelet Biogenesis – Leslie Williams, Director, Founder, President and CEO, ImmusanT

11:30am – 12:15pm: Financing Outlook for 2019-2020: Will the Bubble Burst? [Business Track] 2018 was a record year for biotech IPOs, the XBI hit an all-time high in August, and the FDA approved a record number of novel drugs. What will 2019 bring after late 2018’s many signals of a slowing market? Will M&A pick up? Can new IPOs continue at last year’s pace? How will public markets respond? Investment bankers, private equity, and industry leaders peer into their crystal ball to predict the financial outlook for the next few years. – Bruce Booth, Partner, Atlas Ventures

12:15pm – 1:15pm: Lunch and MassBio Innovation Award Presentation

1:15pm – 2:00pm: Enabling Digital Health in the Healthcare Value Chain At its core, digital technologies are increasingly critical in enabling the growth of biotechnology companies– from the development of better research and development insight engines, to the commercialization of next generation therapies via digital channels. This panel will explore best practices that enable the embedding of digital health technologies in the value chain for both life sciences companies, payers and providers.

2:00pm – 2:30pm: Keynote Address

2:30pm – 3:00pm: Closing Networking Dessert Reception